Daiichi Sankyo Markets Inavir Flu Drug To Compete With Tamiflu
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has launched its single-dose influenza drug, Inavir (laninamivir) as a competitor for Roche's best-sellerTamiflu (oseltamivir)